DANVERS, Mass., Aug. 05, 2015 (GLOBE NEWSWIRE) -- Abiomed, Inc. (NASDAQ:ABMD) announced today that the Company will webcast presentations at its Investor Day held in Boston, MA on Tuesday, August 11, 2015, from 9:00 a.m. to approximately 12:00 p.m. EDT.
Abiomed will host a physician panel of experts, present our corporate strategy and 5 year revenue projection, describe a new patient population of interest and unveil a future product for heart failure.
Company speakers scheduled to present include:
- Michael Minogue, Chief Executive Officer, President & Chairman
- Andrew Greenfield, Vice President & General Manager of Global Marketing
- Thorsten Siess, Chief Technology Officer
- David Weber, Chief Operating Officer
Abiomed invites the public and media to listen to the presentations via a live webcast that can be accessed under the Investor section of the company's website at www.abiomed.com. The presentations are scheduled to begin at approximately 9:00 a.m. EDT. A replay of the webcast will be available on the Abiomed website for a brief period after the event.
If you are interested in attending the Investor Day in Boston, MA, please contact the Investor Relations department at Abiomed, which may be reached at firstname.lastname@example.org.
Based in Danvers, Massachusetts, Abiomed, Inc., is a leading provider of medical devices that provide circulatory support. Our products are designed to enable the heart to rest by improving blood flow and/or performing the pumping of the heart. For additional information please visit: www.abiomed.com
This release includes forward-looking statements, including statements regarding the development and commercialization of Abiomed's existing and new products, the Company's progress toward commercial growth and future financial performance as well as future opportunities and expected submissions to and approvals from regulatory bodies. Each forward-looking statement contained in this release is subject to risks and uncertainties that could cause actual results to differ materially from those projected in such statement. Such risks and uncertainties include uncertainties associated with development, testing and related regulatory approvals, including the potential for future losses, complex manufacturing, high quality requirements, dependence on limited sources of supply, competition, technological change, government regulation, litigation matters, future capital needs and uncertainty of additional financing. Additional information regarding these and other factors appear under the heading “Item 1A. Risk Factors” in our Annual Report on Form 10-K for the year ended March 31, 2015 that is filed with the Securities and Exchange Commission (the “SEC”) and available at www.sec.gov and on our website at www.abiomed.com, as well as subsequent filings with the SEC. The forward-looking statements in this release speak only as of the date of this release and we undertake no obligation to update or revise any of these statements.
For further information please contact: Ingrid Goldberg Director, Investor Relations 978-646-1590 email@example.com